Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].

本次交易构成与关联方及专业投资机构共同投资，不构成《上市公司重大资 产重组管理办法》规定的重大资产重组。 交易实施尚需履行的审批及其他相关程序：本次交易无需提交股东大会审议， 无需经过有关部门批准。 过去 12 个月内，除日常关联交易外，公司与东阿阿胶股份有限公司（以下 简称"东阿阿胶"）全资子公司东阿阿胶医药贸易有限公司投资签订合资经营协议， 共同参与设立华润（甘肃）中药科技有限公司，其中东阿阿胶医药贸易有限公司持 股占比 39%，本公司出资 500 万元，持股占比 10%。东阿阿胶为公司关联方，前述交 易属于《上海证券交易所股票上市规则》规定的公司在连续 12 个月内发生的与同一 关联人进行的交易。 风险提示： 1 证券代码：600750 证券简称：江中药业 公告编号：2025-037 江中药业股份有限公司 关于参与设立华润医药产业投资基金二期 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 交易简要内容：江中药业股份有限公司（以下简称"江中药业""公司"或 "本公司"）拟与普通合伙 ...

表决情况：3 票同意，0 票反对，0 票弃权。通过本议案。 监事会认为，公司本次以自有资金参与设立华润医药产业投资基金二期暨 关联交易事项符合公司战略发展规划，不会对公司财务及经营状况产生重大不 利影响。本次关联交易的审议及决策程序合法合规，不存在损害公司及股东、 特别是中小股东利益的情形。监事会同意公司参与设立华润医药产业投资基金 二期暨关联交易的事项。 特此公告。 证券代码：600750 证券简称：江中药业 公告编号：2025-036 江中药业股份有限公司 第十届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"）第十届监事会第六次会议于 2025 年 7 月 16 日在公司会议室以现场结合视频方式召开，会议通知于 2025 年 7 月 11 日以书面形式发出，应参会监事 3 人，实到 3 人。会议召集召开符合 《公司法》和《公司章程》的有关规定。 会议由监事会主席周娇女士主持，经与会监事认真讨论，审议通过以下议 案： 一、关于参与设立华润医药产业投资基金 ...

Core Insights - The report indicates that over 150 million people in China suffer from liver-related issues such as fatty liver and hepatitis, with 80% of early liver damage showing no obvious symptoms [1][2][5] - The rising awareness of health management has led to a diversified demand for health products, particularly liver health products, which are gaining traction among younger consumers [1][2][4] - The liver health market in China is projected to exceed 80 billion yuan this year, positioning it as a star segment within the broader health market [5] Market Trends - The liver health product market has been experiencing rapid growth since 2012, driven by core demands such as metabolism promotion, dietary regulation, and improvement of physical and mental states [4][6] - The demographic of liver health product consumers is shifting, with 35% of consumers in 2023 aged between 26 and 35, making this age group the largest and fastest-growing segment [4][6] Product Offerings - Various forms of liver health products are emerging, including liver tea, liver protection tablets, liver capsules, and health-enhanced gummies, catering to different age groups and health conditions [6] - Natural ingredient-rich liver health products are particularly favored by consumers [4] Sales Channels - Traditional direct sales are declining, with pharmacies, shopping malls, and online platforms becoming the primary purchasing channels, especially e-commerce, which is expected to continue growing due to the younger generation's health consciousness [6][7] - Local brands are achieving significant sales, with some health products surpassing 500 million yuan in annual sales [7]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. announced a cash dividend of 0.7 yuan per share, totaling approximately 444.5 million yuan, to be distributed to shareholders on June 20, 2025 [1][5]. Dividend Distribution Plan - The cash dividend distribution is based on a total share capital of 634,996,022 shares, with a total cash dividend payout of 444,497,215.4 yuan [1]. - The key dates for the dividend distribution are as follows: - Record date: June 19, 2025 - Ex-dividend date: June 20, 2025 - Cash dividend payment date: June 20, 2025 [1]. Taxation on Dividends - For individual shareholders holding shares for more than one year, the dividend income is exempt from personal income tax [3][4]. - For shares held between one month and one year, a tax of 0.07 yuan per share will be deducted, while shares held for one month or less will incur a tax of 0.14 yuan per share [4]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.63 yuan per share [4][5]. Contact Information - For inquiries regarding the dividend distribution plan, shareholders can contact the company's investment securities department at 0791-88169323 [5].

证券代码：600750 证券简称：江中药业 公告编号：2025-035 江中药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 3. 分配方案： 本次利润分配以方案实施前的公司总股本634,996,022股为基数，每股派发现 金红利0.7元（含税），共计派发现金红利444,497,215.4元。 三、相关日期 每股分配比例 A 股每股现金红利0.7元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经江中药业股份有限公司（以下简称"公司"）2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公 ...

Core Points - The company has completed the initial grant registration of its second phase restricted stock incentive plan, granting 6,128,000 shares at a price of 13.70 yuan per share to 165 eligible participants [1][2][5] - The plan's effective period lasts up to 120 months, with a lock-up period of 24, 36, and 48 months for the granted shares [7][8] - The total subscription amount received from the participants is 83,953,600 yuan, which will be used to supplement the company's working capital [15][17] Grant Details - The initial grant date was set for May 16, 2025, with the actual number of shares granted adjusted to 6,128,000 due to three participants voluntarily giving up their shares [2][5] - The stock source is from the company's directed issuance of A-share common stock [3] - The registration of the granted shares was completed on June 6, 2025 [15] Lock-up and Release Conditions - The lock-up period for the granted shares is divided into three phases, with restrictions on transfer, collateral use, or debt repayment during this time [8] - The release of the shares is contingent upon meeting specific performance conditions at both the company and individual levels over the assessment period from 2025 to 2027 [12][14] Financial Impact - The company will recognize the cost of the stock grants based on the fair value determined at the grant date, impacting its financial statements [16][17] - The total share capital will increase by 6,128,000 shares, leading to a dilution of the controlling shareholder's stake from 43.25% to 42.84% without affecting control [15][17]

证券代码：600750 证券简称：江中药业 公告编号：2025-034 江中药业股份有限公司 关于第二期限制性股票激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司股权激励管理办法》、上海证券交 易所、中国证券登记结算有限责任公司上海分公司的有关规定，江中药业股份有 限公司（以下简称"公司"）已完成公司第二期限制性股票激励计划（以下简称 "本激励计划"）的首次授予登记工作，有关具体情况如下： 一、本激励计划首次授予情况 公司于 2025 年 5 月 16 日召开第十届董事会第五次会议和第十届监事会第五 次会议，审议通过了《关于江中药业第二期限制性股票激励计划向激励对象首次 授予限制性股票的议案》，确定本激励计划的首次授予日为 2025 年 5 月 16 日， 向符合条件的 168 名激励对象授予 621.7 万股限制性股票，授予价格为 13.70 元 /股。公司薪酬与考核委员会已事前审议通过该议案，监事会同意该议案并出具 了核查意见。 在确定授予 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-033 江中药业股份有限公司 关于 2021 年限制性股票激励计划预留授予部分 第二个解除限售期解锁暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 139,938股。 本次股票上市流通总数为139,938股。 本次股票上市流通日期为2025 年 5 月 30 日。 江中药业股份有限公司（以下简称"公司"）第十届董事会第四次会议和第十 届监事会第四次会议审议通过了《关于公司 2021 年限制性股票激励计划预留授予 部分第二个解锁期解锁条件成就的议案》。根据《2021 年限制性股票激励计划（2022 年 11 月修订稿）》（以下简称"激励计划"）的有关规定和公司 2021 年第二次临时 股东大会的授权，公司董事会认为公司激励计划规定的预留授予部分限制性股票 第二个解除限售期解除限售条件已经成就。具体内容详见 2025 年 4 月 26 日公司 刊登于上海证券报、中国证券报 ...

Core Points - The company announced the repurchase and cancellation of restricted stocks due to five incentive targets no longer meeting the criteria of the 2021 stock incentive plan [1][2] - A total of 149,602 restricted stocks will be repurchased and canceled, leaving 1,715,544 restricted stocks remaining under the incentive plan [2][3] - The repurchase is expected to be completed by May 23, 2025, with necessary legal and registration procedures to follow [3][4] Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks are based on the non-compliance of five incentive targets due to reasons such as job transfer, retirement, and resignation [2][4] Repurchase Details - The decision for the repurchase was approved in the board meetings held on March 18, 2025, and the legal opinion was obtained [1][4] - The company has opened a special securities account for the repurchase with the China Securities Depository and Clearing Corporation [3] Company Commitments - The board assures that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive targets or creditors [4][5] - The company commits to handling any legal responsibilities arising from disputes related to the repurchase [4]